Abstract:Background The clinical importance of rheumatoid arthritis-associated interstitial lung disease has been increased because the usual interstitial pneumonia (UIP) is the most common subtype of interstitial lung disease (ILD) on high-resolution computed tomography (HRCT) in rheumatoid arthritis (RA)and has poor survival rate compared to other forms of ILD related to connective tissue disease. Objectives The clinical characteristics and laboratory data of RA patients with and without ILD were compared in order to clarify the risk factors for ILD in RA patients. Furthermore, risk factors of mortality in the RA patients with ILD group were analyzed. Methods A total of 77 RA patients with ILD and 231 age/sex-, and disease duration-matched RA patients without ILD who were followed from 1991 to 2011 at Seoul National University Hospital were enrolled in this study. Epidemiologic, clinical, and laboratory information including rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) were obtained through medical chart review. The erythrocyte sedimentation rates (ESR), C-reactive protein (CRP) levels, presence of erosion on joint X-rays, and mean corticosteroid doses were examined in order to compare RA outcomes between the RA patients with and without ILD. Cox proportional hazard models were used to estimate the risk of mortality in the RA patients with ILD. Results In the RA with ILD group, the titers of the RF and the anti-CCP were significantly higher compared with those in the RA without ILD group (p=0.001 for both). The RA patients with ILD had higher frequency of a history of tuberculosis or nontuberculous mycobacteria (NTM) (p=0.022). In addition, the RA with ILD group exhibited higher levels of CRP at the time of RA diagnosis (p=0.014) and higher ESR (p=0.022) and CRP levels (p<0.001) throughout the 10-year follow-up period. These patients received higher mean daily dose of corticosteroid (p<0.001). In the subgroup analysis of RA patients with ILD, 28 (36.4%) patients died with the mean follow-up duration of 8.7 years. Male patients, high RF titers and UIP subtype on HRCT had significantly worse survival, and those with nonspecific interstitial pneumonia (NSIP) on HRCT had better survival. In the multivariate analysis, a UIP subtype on HRCT and older age at the time of ILD diagnosis were significantly associated with mortality of RA with ILD. Conclusions The RA patients with ILD had higher RF and anti-CCP titers and baseline CRP levels compared with those without ILD. A UIP subtype on HRCT and older age at the time of the diagnosis of ILD were significantly associated with mortality of RA with ILD. Disclosure of Interest None declared

The additional treatment value of immunoglobulin for the treatment of rheumatoid arthritis complicated with interstitial lung disease: A propensity score-matched pilot study

Overview of Rheumatoid Arthritis-Associated Interstitial Lung Disease and Its Treatment

Efficacy and safety of iguratimod in the treatment of rheumatic and autoimmune diseases: a meta-analysis and systematic review of 84 randomized controlled trials

AB0356 Comparison of the Clinical Characteristics of Rheumatoid Arthritis Patients with and Without Interstitial Lung Disease

SAT0213 Low Dose Il-2 Restores Decreased Absolute Number of Regulatory T Cells and Imbalance Between Th17 and Regulatory T Cells in Patients with Rheumatoid Arthritis

Insights from a 12-Month Trial Using Semi-Quantitative Chest High-Resolution Computed Tomography Imaging

Efficacy of non-conventional synthetic DMARDs for patients with rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis

Antifibrotics in the Management of Rheumatoid Arthritis-Associated Interstitial Lung Disease: Prospective Real-World Experience From an Interstitial Lung Disease Clinic in India

Subcutaneous vs intravenous abatacept in rheumatoid arthritis-interstitial lung disease. National multicentre study of 397 patients

SAT0163 Absolute Number of Peripheral Cd4-Cd25+foxp3+t Cells Decreases and Restores after Low-Dose Interleukin-2 Treatment in Rheumatoid Arthritis

Effect of N-Acetylcysteine Combined with Lung Rehabilitation Therapy on Exercise Endurance and Quality of Life of Patients with Rheumatoid Arthritis-Related Interstitial Lung Disease

The efficacy and safety of short-term and low-dose IL-2 combined with tocilizumab to treat rheumatoid arthritis

Inflammatory Biomarkers in the Diagnosis and Prognosis of Rheumatoid Arthritis–Associated Interstitial Lung Disease

A retrospective study of the efficacy of JAK inhibitors or abatacept on rheumatoid arthritis-interstitial lung disease

Short-term efficiency of plasma exchange in combination with immunosuppressants and/or biologics in the treatment of idiopathic inflammatory myopathy with rapidly progressive interstitial lung disease: a systematic review and meta-analysis

Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicentre retrospective study

Abatacept versus tumor necrosis factor inhibitors on mortality and medical utilizations in the treatment of rheumatoid arthritis associated interstitial lung disease: a large-scale real-world retrospective cohort study

Potential Rheumatoid Arthritis-Associated Interstitial Lung Disease Treatment and Computational Approach for Future Drug Development

Expression and diagnostic value of interleukin-22 in rheumatoid arthritis-associated interstitial lung disease

Risk factors for progression and prognosis of rheumatoid arthritis–associated interstitial lung disease: single center study with a large sample of Chinese population

Efficacy and safety of abatacept in interstitial lung disease of rheumatoid arthritis: A systematic literature review